

## S 1250

### Drug-price Transparency for Consumers Act of 2023

**Congress:** 118 (2023–2025, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Apr 20, 2023

**Current Status:** Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1)

**Latest Action:** Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1297; text: CR S1297-1298) (Apr 20, 2023)

**Official Text:** <https://www.congress.gov/bill/118th-congress/senate-bill/1250>

### Sponsor

**Name:** Sen. Durbin, Richard J. [D-IL]

**Party:** Democratic • **State:** IL • **Chamber:** Senate

### Cosponsors (8 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Baldwin, Tammy [D-WI]	D · WI		Apr 20, 2023
Sen. Blumenthal, Richard [D-CT]	D · CT		Apr 20, 2023
Sen. Braun, Mike [R-IN]	R · IN		Apr 20, 2023
Sen. Grassley, Chuck [R-IA]	R · IA		Apr 20, 2023
Sen. King, Angus S., Jr. [I-ME]	I · ME		Apr 20, 2023
Sen. Vance, J. D. [R-OH]	R · OH		Apr 20, 2023
Sen. Brown, Sherrod [D-OH]	D · OH		Jul 12, 2023
Sen. Smith, Tina [D-MN]	D · MN		Sep 7, 2023

### Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Apr 20, 2023

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
118 HR 5958	Identical bill	Dec 17, 2024: Referred to the Subcommittee on Health.

## **Drug-price Transparency for Consumers Act of 2023 or the DTC Act of 2023**

This bill requires consumer advertisements for drugs and biologicals to include certain price information if the drug or biological is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law. The requirement does not apply to advertisements for drugs or biologicals with a wholesale cost of less than \$35 for a one-month supply.

Each violation of this requirement is subject to a civil penalty of not more than \$100,000.

### **Actions Timeline**

---

- **Apr 20, 2023:** Introduced in Senate
- **Apr 20, 2023:** Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1297; text: CR S1297-1298)